RESUMEN
Chemical vectors are widely developed for providing safe DNA delivery systems. It is well admitted that their endocytosis and intracellular trafficking are critical for the transfection efficiency. Here, we have compared the endocytic pathways of lipoplexes, polyplexes and lipopolyplexes formed with carriers of various chemical compositions. Engineered C2C12 mouse myoblast cells expressing Rab5-EGFP, Rab7-EGFP or Cav1-GFP were used to monitor the location of the plasmid DNA into the endocytic compartments by real time fluorescence confocal microscopy. We observed that (i) DNA complexes made with dioleyl succinyl paromomycin:O,O-dioleyl-N-histamine phosphoramidate (DOSP/MM27) liposomes or histidinylated lPEI (His-lPEI) allowing the highest transfection efficiency displayed a positive ζ potential and were internalized by clathrin-mediated endocytosis, (ii) DOSP/MM27 lipoplexes were 6-times more internalized than His-lPEI polyplexes, (iii) all negatively charged DNA complexes lead to less efficient transfection and entered the cells via caveolae and (iv) lipopolyplexes allowing high transfection efficiency were weakly internalized via caveolae. Our results indicate that the transfection efficiency is better correlated with the nature of the endocytic pathway than with the uptake efficacy. This study shows also that engineered cells expressing specific fluorescent compartments are convenient tools to monitor endocytosis of a fluorescent plasmid DNA by real time fluorescence confocal microscopy.
Asunto(s)
Endocitosis , Técnicas de Transferencia de Gen , Liposomas/química , Mioblastos/metabolismo , Polímeros/química , Animales , Caveolina 1/metabolismo , Muerte Celular , Línea Celular , Supervivencia Celular , ADN/metabolismo , Proteínas Fluorescentes Verdes/metabolismo , Espacio Intracelular/metabolismo , Luciferasas/metabolismo , Ratones , Mioblastos/citología , Plásmidos/metabolismo , Proteínas Recombinantes de Fusión/metabolismo , Transfección , Transferrina/metabolismo , Proteínas de Unión al GTP rab/metabolismo , Proteínas de Unión al GTP rab5/metabolismo , Proteínas de Unión a GTP rab7RESUMEN
A series of linear polyethylenimine (lPEI) substituted with histidine residue (His-lPEI) was synthesized using the Michael reaction in order to provide new highly efficient vectors for gene therapy applications (up to 95% of transfected cells) with remarkable low cytotoxicity compared to lPEI-based polyplexes.
Asunto(s)
Portadores de Fármacos/química , Histidina/química , Polietileneimina/química , Transfección/métodos , Portadores de Fármacos/toxicidad , Células HEK293 , Células HeLa , Humanos , Polietileneimina/toxicidadRESUMEN
Chemical vectors for non-viral gene delivery are based on engineered DNA nanoparticles produced with various range of macromolecules suitable to mimic some viral functions required for gene transfer. Many efforts have been undertaken these past years to identify cellular barriers that have to be passed for this issue. Here, we summarize the current status of knowledge on the uptake mechanism of DNA nanoparticles made with polymers and liposomes, their endosomal escape, cytosolic diffusion, and nuclear import of pDNA. Studies reported these past years regarding pDNA nanoparticles endocytosis indicated that there is no clear evident relationship between the ways of entry and the transfection efficiency. By contrast, the sequestration of pDNA in intracellular vesicles and the low number of pDNA close to the nuclear envelop are identified as the major intracellular barriers. So, intensive investigations to increase the cytosolic delivery of pDNA and its migration toward nuclear pores make sense to bring the transfection efficiency closer to that of viruses.
Asunto(s)
Técnicas de Transferencia de Gen , Vectores Genéticos/química , Vectores Genéticos/metabolismo , Transporte Biológico , Núcleo Celular/metabolismo , Endosomas/metabolismo , Liposomas/química , Liposomas/metabolismo , Modelos Biológicos , Polímeros/química , Polímeros/metabolismoRESUMEN
In a previous study, we identified the regulated in development and DNA damage response 2 (REDD2) gene as a highly expressed gene in human atherosclerotic lesions in comparison to normal artery, as well as in cultured human macrophages, and showed its implication in oxidized low-density lipoprotein (LDL)-induced macrophage death sensitivity. In this article, we attempt to identify the mechanism by which REDD2 induces such a phenomenon. Transient transfection of U-937 monocytic cells with a pCI.CMV.REDD2 expression vector increased by approximately twofold the mRNA levels of REDD2 in comparison to control cells transfected with pCI.CMV.GFP. Reactive oxygen species (ROS) production was significantly induced in REDD2-transfected cells compared with control cells (157+/-48 and 100+/-8 arbitrary units/mg cell protein, respectively; p<0.05). Moreover, a significant increase in parameters known to reflect the oxidative modifications of LDL was observed. Among enzymes involved in ROS production or degradation, we found a specific reduction in thioredoxin-1 (Trx-1) mRNA ( approximately 52+/-7% decrease, p<0.01 vs control cells) and protein ( approximately 60+/-4% decrease, p<0.001 vs control cells) levels in cells overexpressing REDD2 in comparison to control cells. In contrast, transfection of U-937 cells with siRNA against REDD2 decreased the mRNA levels of REDD2 by approximately 60% and increased Trx-1 mRNA and protein levels. Moreover, we observed no or a moderate increase in Bax (proapoptotic) and a significant decrease in Bcl2 (antiapoptotic) gene expression in cells that overexpress REDD2 compared to control cells. In addition, we showed that Trx-1 mRNA and protein levels were increased at low H(2)O(2) doses and decreased at higher doses. Interestingly, macrophages isolated from human atherosclerotic lesions differentially express REDD2 and Trx-1. Indeed, in certain patients, levels of REDD2 mRNA were low and those of Trx-1 mRNA were high. In contrast, in other patients, levels of REDD2 were high and levels of Trx-1 mRNA were low.
Asunto(s)
Monocitos/metabolismo , Proteínas/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Tiorredoxinas/metabolismo , Proteína X Asociada a bcl-2/metabolismo , Proteínas Adaptadoras Transductoras de Señales , Apoptosis , Aterosclerosis/enzimología , Aterosclerosis/genética , Aterosclerosis/fisiopatología , Clonación Molecular , Regulación de la Expresión Génica , Humanos , Peróxido de Hidrógeno/metabolismo , Lipoproteínas LDL/análisis , Monocitos/patología , Estrés Oxidativo , Proteínas/genética , Proteínas Proto-Oncogénicas c-bcl-2/genética , ARN Interferente Pequeño/genética , Especies Reactivas de Oxígeno , Tiorredoxinas/genética , Transfección , Células U937 , Proteína X Asociada a bcl-2/genéticaRESUMEN
The regulation of cellular reduction/oxidation (redox) balance is critically determined by several antioxidant systems such as the thioredoxin-1 (Trx-1) which reduces disulfides on targeted proteins. In addition, intracellular Trx-1 exerts most of its antioxidant properties through scavenging of reactive oxygen species. Moreover, it acts as a cofactor for several enzymes and plays an important role in the regulation of redox-sensitive transcription factors. Several studies have reported that Trx-1 activity can be modulated by the interaction with vitamin D3-upregulated protein (VDUP-1) (also called Txnip for thioredoxin interacting protein-1 or TBP-2 for Trx-binding protein-2). Trx-1 secretion has been reported to occur in conditions associated with oxidative stress and inflammation. Beneficial effects of elevated plasma Trx-1 levels on various pathologies were reported in mice. In conclusion, oxidative stress is an important actor in various pathologies including cardio- and cerebro-vascular diseases. Therefore, controlling the redox status by increasing the activity of Trx-1 seems to be a novel and an attractive approach.
Asunto(s)
Enfermedades Cardiovasculares/tratamiento farmacológico , Estrés Oxidativo/efectos de los fármacos , Tiorredoxinas/metabolismo , Animales , Antioxidantes/metabolismo , Enfermedades Cardiovasculares/fisiopatología , Trastornos Cerebrovasculares/tratamiento farmacológico , Trastornos Cerebrovasculares/fisiopatología , Sistemas de Liberación de Medicamentos , Humanos , Oxidación-Reducción , Especies Reactivas de Oxígeno/metabolismo , Tiorredoxinas/efectos de los fármacosRESUMEN
MMP-12, a macrophage-specific matrix metalloproteinase with large substrate specificity, has been reported to be highly expressed in mice, rabbits and human atherosclerotic lesions. Increased MMP-12 from inflammatory macrophages is associated with several degenerative diseases such as atherosclerosis. In this manuscript, we show that IL-1beta, a proinflammatory cytokine found in atherosclerotic plaques, increases both mRNA and protein levels of MMP-12 in human monocyte-derived macrophages (HMDM). Since peroxisome proliferator-activated receptors (PPARs), such as PPARalpha and PPARgamma, are expressed in macrophages and because PPAR activation exerts an anti-inflammatory effect on vascular cells, we have investigated the effect of PPARalpha and gamma isoforms on MMP-12 regulation in HMDM. Our results show that MMP-12 expression (mRNA and protein) is down regulated in IL-1beta-treated macrophages only in the presence of a specific PPARalpha agonist, GW647, in a dose-dependent manner. In contrast, this inhibitory effect was abolished in IL-1beta-stimulated peritoneal macrophages isolated from PPARalpha(-/-) mice and treated with the PPARalpha agonist, GW647. Moreover, reporter gene transfection experiments using different MMP-12 promoter constructs showed a reduction of the promoter activities by approximately 50% in IL-1beta-stimulated PPARalpha-pre-treated cells. However, MMP-12 promoter analysis did not reveal the presence of a PPRE response element. The IL-1beta effect is known to be mediated through the AP-1 binding site. Mutation of the AP-1 site, located at -81 in the MMP-12 promoter region relative to the transcription start site, followed by transfection analysis, gel shift and ChIP experiments revealed that the inhibitory effect was the consequence of the protein-protein interaction between GW 647-activated PPARalpha and c-Fos or c-Jun transcription factors, leading to inhibition of their binding to the AP-1 motif. These studies suggest that PPARalpha agonists may be used therapeutically, not only for lipid disorders, but also to prevent inflammation and atheromatous plaque rupture, where their ability to inhibit MMP-12 expression in HMDM may be beneficial.
Asunto(s)
Regulación de la Expresión Génica/efectos de los fármacos , Macrófagos Peritoneales/efectos de los fármacos , Macrófagos Peritoneales/enzimología , Metaloproteinasa 12 de la Matriz/metabolismo , Monocitos/enzimología , PPAR alfa/agonistas , Animales , Sitios de Unión/genética , Relación Dosis-Respuesta a Droga , Regulación hacia Abajo , Humanos , Interleucina-1beta/farmacología , Metaloproteinasa 12 de la Matriz/genética , Ratones , Ratones Noqueados , PPAR alfa/antagonistas & inhibidores , PPAR alfa/metabolismo , PPAR gamma/metabolismo , Regiones Promotoras Genéticas , ARN Mensajero/biosíntesisRESUMEN
Macrophage-derived reactive oxygen species contribute to the initiation and development of atherosclerosis. The cellular balance between oxidative and reductive states depends on the endogenous antioxidant capacity, with the thioredoxin-1 (Trx-1) system playing a major role. Peroxisome proliferator-activated receptor-alpha (PPARalpha) is expressed by human macrophages and exhibits anti-inflammatory properties. Here we show that the selective PPARalpha activator GW647 significantly increased the Trx-1 mRNA and protein expression in human macrophages as determined by quantitative polymerase chain reaction and Western immunoblotting. Consistently, the Trx-1 activity was significantly increased by PPARalpha activation. By contrast, PPARalpha activation led to the down-regulation of vitamin D(3) up-regulated protein 1 (VDUP-1), the physiological inhibitor of Trx-1. Analysis of the Trx-1 and VDUP-1 promoters with gene reporter assays, mutational analysis, gel shift assays and chromatin immunoprecipitation analyses revealed the presence of a functional response element specific for PPARalpha in the Trx-1 promoter and the presence of a functional activator protein 1 (AP-1) site in the VDUP-1 promoter. The interference of PPARalpha/retinoid X receptor alpha with the AP-1 transcription factor elements c-Jun/c-Fos resulted in the inhibition of AP-1 binding and down-regulation of the VDUP-1 gene expression. Finally, PPARalpha activation reduced the lidocaine-induced caspase-3 activity and apoptosis, which might be due to the VDUP-1-mediated regulation of the Bax/Bcl-2 ratio. Together these data indicate that stimulation of PPARalpha in human macrophages might reduce arterial inflammation through differential regulation of the Trx-1 and VDUP-1 gene expression.
Asunto(s)
Proteínas Portadoras/biosíntesis , Regulación de la Expresión Génica , Macrófagos/metabolismo , PPAR alfa/metabolismo , Tiorredoxinas/biosíntesis , Apoptosis , Secuencia de Bases , Sitios de Unión , Butiratos/farmacología , Cromatina/metabolismo , Humanos , Datos de Secuencia Molecular , Estrés Oxidativo , PPAR alfa/agonistas , Compuestos de Fenilurea/farmacología , Regiones Promotoras Genéticas , Unión Proteica , Factor de Transcripción AP-1/metabolismoRESUMEN
OBJECTIVE: In this article, we studied the effect of acetyl-11-keto-beta-boswellic acid (AKbetaBA), a natural inhibitor of the proinflammatory transcription factor NF-kappaB on the development of atherosclerotic lesions in apolipoprotein E-deficient (apoE-/-) mice. METHODS AND RESULTS: Atherosclerotic lesions were induced by weekly LPS injection in apoE-/- mice. LPS alone increased atherosclerotic lesion size by approximately 100%, and treatment with AKbetaBA significantly reduced it by approximately 50%. Moreover, the activity of NF-kappaB was also reduced in the atherosclerotic plaques of LPS-injected apoE-/- mice treated with AKbetaBA. As a consequence, AKbetaBA treatment led to a significant downregulation of several NF-kappaB-dependent genes such as MCP-1, MCP-3, IL-1alpha, MIP-2, VEGF, and TF. By contrast, AKbetaBA did not affect the plasma concentrations of triglycerides, total cholesterol, antioxidized LDL antibodies, and various subsets of lymphocyte-derived cytokines. Moreover, AKbetaBA potently inhibited the IkappaB kinase (IKK) activity immunoprecipitated from LPS-stimulated mouse macrophages and mononuclear cells leading to decreased phosphorylation of IkappaB alpha and inhibition of p65/NF-kappaB activation. Comparable AKbetaBA-mediated inhibition was also observed in LPS-stimulated human macrophages. CONCLUSIONS: The inhibition of NF-kappaB activity by plant resins from species of the Boswellia family might represent an alternative for classical medicine treatments for chronic inflammatory diseases such as atherosclerosis.
Asunto(s)
Apolipoproteínas E/genética , Aterosclerosis/tratamiento farmacológico , FN-kappa B/antagonistas & inhibidores , FN-kappa B/efectos de los fármacos , Extractos Vegetales/farmacología , Triterpenos/farmacología , Animales , Aterosclerosis/genética , Boswellia , Células Cultivadas , Modelos Animales de Enfermedad , Inflamación/tratamiento farmacológico , Lipopolisacáridos/administración & dosificación , Lipopolisacáridos/inmunología , Ratones , Ratones NoqueadosRESUMEN
Oxidative stress plays an important role in atherosclerotic vascular disease, and several recent studies were focused on thioredoxin-1 (Trx-1) and its potential protective role against oxidative stress. Since human monocyte-derived macrophages (HMDM) are important cells in several inflammatory diseases including atherosclerosis, we conducted this study to evaluate the impact of extracellular recombinant human Trx-1 (rhTrx-1) on gene expression in lipopolysaccharide-activated HMDM. Our results showed that rhTrx-1 was capable of reducing interleukin (IL)-1beta mRNA and protein synthesis in a dose-dependent manner. This effect was partly mediated through a reduction of NF-kappaB activation as analyzed by transient transfection and gel shift assays. In addition, we showed that the attenuation of NF-kappaB activity was the result of the reduction of both p50 and p65 subunit mRNA and protein synthesis on one hand and of the induction of I-kappaBalpha mRNA and protein expression on the other hand. Moreover, inhibition of endogenous Trx-1 mRNA was also observed, suggesting a contribution to the diminution of NF-kappaB activity since endogenous Trx-1, in contrast to the exogenous Trx-1, activates the NF-kappaB system. Finally, H2O2-oxidized rhTrx-1 reduced IL-1beta mRNA synthesis in lipopolysaccharide-activated HMDM. This result highly suggested that the rhTrx-1 used in this study could be oxidized in the culture medium and, in turn, reduced IL-1beta mRNA and protein synthesis. Taken together, these data indicated a potential new mechanism through which extracellular rhTrx-1 exerts an anti-inflammatory function in HMDM.